Status:

UNKNOWN

Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

Lead Sponsor:

Seoul National University Hospital

Conditions:

Multiple Myeloma in Relapse

Plasmacytoma

Eligibility:

All Genders

19+ years

Phase:

PHASE2

Brief Summary

This trial aimed to investigate the therapeutic efficacy of daratumumnab plus chemitherapy in multiple myeloma with plasmacytoma.

Detailed Description

Multiple myeloma with plasmacytoma is a disease with significantly short overall survival. Cancer cells in plasmacytoma has inferior response compared to cancer cells in bone marrow in multiple myelom...

Eligibility Criteria

Inclusion

  • ECOG performance status 2 or better Adequate physical condition that could tolerate cytotoxic chemotherapy judged by investigator Relapsed/Refractory Multiple myeloma with plasmacytoma Adequate cardiac function , hepatic and renal function Adequate hematopoietic function i. White blood cells ≥3000 ii. Absolute neutrophil count ≥1500 iii. Platelets ≥50,000 iv. Hemoglobin \>7.5mg/dL ( Transfusion is not permitted within 2 weeks.) v. Total bilirubin \<1.5 times upper limit of normal vi. AST and ALT \<1.5 times upper limit of normal vii. Serum creatinine \<1.5 times upper limit of normal Singed and dated informed consent of document indicating that the patient(or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment For women of child bearing age, it should be confirmed that they are not pregnant and that they should be contraception during the study period and for up to 3 months after the end of study Male should agree to the barrier method during the study period and up to 3 months after the end of the study

Exclusion

  • HSCT (hematopoietic stem cell transplantation) within the last 12 weeks
  • Other severe acute or

Key Trial Info

Start Date :

January 14 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2021

Estimated Enrollment :

33 Patients enrolled

Trial Details

Trial ID

NCT04065308

Start Date

January 14 2019

End Date

September 30 2021

Last Update

August 22 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Seoul National University Hospital

Seoul, South Korea